搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Vibrio harveyi ATP synthase subunit b 1 (atpF1), partial CSB-YP418493VEA
CSB-EP418493VEA
CSB-BP418493VEA
CSB-MP418493VEA
CSB-EP418493VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Coproporphyrinogen-III oxidase, aerobic (hemF) CSB-YP418494VEA
CSB-EP418494VEA
CSB-BP418494VEA
CSB-MP418494VEA
CSB-EP418494VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Glycine--tRNA ligase beta subunit (glyS), partial CSB-YP418495VEA
CSB-EP418495VEA
CSB-BP418495VEA
CSB-MP418495VEA
CSB-EP418495VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Ribosomal RNA large subunit methyltransferase M (rlmM) CSB-YP418496VEA
CSB-EP418496VEA
CSB-BP418496VEA
CSB-MP418496VEA
CSB-EP418496VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Chaperone protein TorD (torD) CSB-YP418497VEA
CSB-EP418497VEA
CSB-BP418497VEA
CSB-MP418497VEA
CSB-EP418497VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Putative arginyl-tRNA--protein transferase (ate) CSB-YP418498VEA
CSB-EP418498VEA
CSB-BP418498VEA
CSB-MP418498VEA
CSB-EP418498VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi 50S ribosomal protein L31 type B (rpmE2) CSB-YP418499VEA
CSB-EP418499VEA
CSB-BP418499VEA
CSB-MP418499VEA
CSB-EP418499VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi HTH-type transcriptional regulator BetI (betI) CSB-YP418500VEA
CSB-EP418500VEA
CSB-BP418500VEA
CSB-MP418500VEA
CSB-EP418500VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Probable manganese transport protein MntH (mntH), partial CSB-YP418501VEA
CSB-EP418501VEA
CSB-BP418501VEA
CSB-MP418501VEA
CSB-EP418501VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi HTH-type transcriptional regulator malT (malT), partial CSB-YP418502VEA
CSB-EP418502VEA
CSB-BP418502VEA
CSB-MP418502VEA
CSB-EP418502VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Protoheme IX farnesyltransferase 2 (cyoE2), partial CSB-YP418503VEA
CSB-EP418503VEA
CSB-BP418503VEA
CSB-MP418503VEA
CSB-EP418503VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Isopentenyl-diphosphate delta-isomerase (fni) CSB-YP418504VEA
CSB-EP418504VEA
CSB-BP418504VEA
CSB-MP418504VEA
CSB-EP418504VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi UPF0312 protein VIBHAR_05924 (VIBHAR_05924) CSB-YP418505VEA
CSB-EP418505VEA
CSB-BP418505VEA
CSB-MP418505VEA
CSB-EP418505VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica Ribosomal RNA small subunit methyltransferase G (rsmG) CSB-YP418506FDV
CSB-EP418506FDV
CSB-BP418506FDV
CSB-MP418506FDV
CSB-EP418506FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 30S ribosomal protein S12 (rpsL) CSB-YP418507FDV
CSB-EP418507FDV
CSB-BP418507FDV
CSB-MP418507FDV
CSB-EP418507FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 50S ribosomal protein L2 (rplB) CSB-YP418508FDV
CSB-EP418508FDV
CSB-BP418508FDV
CSB-MP418508FDV
CSB-EP418508FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 30S ribosomal protein S14 (rpsN) CSB-YP418509FDV
CSB-EP418509FDV
CSB-BP418509FDV
CSB-MP418509FDV
CSB-EP418509FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 30S ribosomal protein S11 (rpsK) CSB-YP418510FDV
CSB-EP418510FDV
CSB-BP418510FDV
CSB-MP418510FDV
CSB-EP418510FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (ispH) CSB-YP418511FDV
CSB-EP418511FDV
CSB-BP418511FDV
CSB-MP418511FDV
CSB-EP418511FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica GTPase Der (der) CSB-YP418512FDV
CSB-EP418512FDV
CSB-BP418512FDV
CSB-MP418512FDV
CSB-EP418512FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>